Complexo Hospitalario Universitario De Pontevedra — Clinical Trial Site

54 Registered trials

15 Currently recruiting

Organisation

Complexo Hospitalario Universitario De Pontevedra

Location

Pontevedra, Spain

Identifier

ORG-100041959

Address

Calle Mourente S/n, 36164, Spain

Departments

#40295: Dermatologia
#7510: Servicio Dermatología
2800:Dermatología
9263: Servicio Dermatología
Allergology
Anestesia
Aparato Digestivo
Consultas Digestivo
Departamento de dermatologia
Dermathology unit
Dermatología
Dermatology
Dermatology Centro Especialidades de Mollabao-3º planta"
Dermatology department
Digestive
Digestive service
Digestive system
Digestivo
Endocrinology
ES10001: Gastroenterologia
ES10014: Gastroenterologia
Gastroenterologia
Gastroenterology department
Hematología
Hematology
Hepathology
Hepatology
Hepatology and Gastroenterology
Hepatology and Gastroenterology Department
Infectious diseases
Infectious Diseases Unit, Service of Internal Medicine
Medical Doctor
N/A
Oncology
Pulmonology
Servicio Aparato Digestivo
Servicio de Dermatología
Tuberculosis Unit - Infectious Diseases
Unidad lípidos/endocrinología

Clinical trials at this site (54)

Search interface

Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended

2023-507204-31-00 Hidradenitis Suppurativa 5 2024-07-26
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas… Ended

2023-503444-13-00 Relapsed/refractory multiple myeloma 5 2023-03-29
A study to assess safety and efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC) Ended

2024-511370-72-00 Primary Sclerosing Cholangitis 4 2023-03-29
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504741-32-00 Moderately to Severely Active Crohn's Disease 4 2022-11-30
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended

2023-504743-13-00 Moderately to Severely Active Ulcerative Colitis 4 2022-11-30
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended

2024-517008-12-00 Newly-diagnosed multiple myeloma (NDMM) 5 2022-10-14
Long-term follow-up study to evaluate durability of treatment response in previous bepirovirsen study participants (B-Sure). Ended

2023-506867-33-01 Chronic Hepatitis B 4 2022-01-25
A clinical study to assess the efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirr… Ended

2023-508248-23-00 Non-alcoholic steatohepatitis (NASH) 5 2021-11-26
Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended

2023-506962-30-00 Non-alcoholic steatohepatitis (NASH) 5 2021-03-29
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80… Ended

2024-512232-30-00 Primary Biliary Cholangitis 10 2021-01-18
A clinical trial to evaluate the safety and effectiveness of MGL-3196 (resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and… Ended

2024-510626-89-00 Non-Alcoholic Steatohepatitis (NASH) 5 2019-11-18
Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year… Ended

2024-516905-22-00 Multiple myeloma 5 2018-10-22
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended

2022-502899-23-00 Hepatic Encephalopathy (OHE) 5 2024-04-23
Comparison of three short rifamycin-based regimens to treat latent tuberculosis in patients with end-stage kidney disease. Ended

2023-506432-32-00 Latent tuberculosis infection in patients with end-stag 6 2024-04-11
RANDOMIZED, CONTROLLED, OPEN, MULTICENTRIC CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION OF ANTI-TUBERCULOUS DRUGS BAS… Ended

2023-509075-17-00 Bacilliferous pulmonary tuberculosis 4 2024-01-17
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Ended

2022-501476-25-00 Atopic Dermatitis Eczema 5 2023-09-12
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501752-29-00 Hidradenitis Suppurativa 5 2023-06-15
ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended

2022-500536-11-01 Moderately to severely active ulcerative colitis 5 2023-06-08
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Atopic Dermatitis 5 2023-05-11
Phase 2b Study of GSK4532990 in Adults with NASH (HORIZON) Ended

2023-507503-62-00 Non-alcoholic Fatty Liver Disease 4 2023-03-30
Prophylaxis of venous thromboembolic disease with LMWH (TINzaparin) in patients with metastatic colorectal cancer who start the first line o… Ended

2023-508860-31-00 Stage IV colon or rectal adenocarcinoma (mCRC). 5 2023-02-28
Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 1) Ended

2023-504239-41-00 Hepatitis B, Chronic 5 2023-01-09
A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or … Ended

2023-504257-12-00 Portal hypertension 4 2022-07-28
Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight… Ended

2023-509668-11-00 Moderate-to-severe plaque psoriasis and a body weight ≥ 6 2022-06-15